Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results

被引：0

作者：

Gettinger, Scott N. ^{[1
]}

Bazhenova, Lyudmila ^{[2
]}

Salgia, Ravi ^{[3
]}

Langer, Corey J. ^{[4
]}

Gold, Kathryn A. ^{[5
]}

Rosell, Rafael ^{[6
,7
]}

Shaw, Alice ^{[8
]}

Weiss, Glen J. ^{[9
]}

Dorer, David J. ^{[10
]}

Rivera, Victor M. ^{[10
]}

Conlan, Maureen G. ^{[10
]}

Kerstein, David ^{[10
]}

Camidge, Ross ^{[11
]}

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[3] Univ Chicago Med, Chicago, IL USA

[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Dexeus Univ Inst, Barcelona, Spain

[7] Catalan Inst Oncol, Barcelona, Spain

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

[9] Canc Treatment Ctr Amer, Goodyear, AZ USA

[10] Ariad Pharmaceut Inc, Cambridge, MA USA

[11] Univ Colorado, Ctr Canc, Aurora, CO USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

NSCLC; TKI; brigatinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL33.06

引用

页码：S238 / S239

页数：2

共 50 条

[31] Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC) [J].

Yang, James Chih-Hsin ;

Ou, Sai-Hong ;

De Petris, Luigi ;

Gadgeel, Shirish ;

Gandhi, Leena ;

Kim, Dong-Wan ;

Barlesi, Fabrice ;

Govindan, Ramaswamy ;

Dingemans, Anne-Marie ;

Crino, Lucio ;

Lena, Herve ;

Popat, Sanjay ;

Ahn, Jin Seok ;

Dansin, Eric ;

Golding, Sophie ;

Bordogna, Walter ;

Balas, Bogdana ;

Morcos, Peter N. ;

Zeaiter, Ali ;

Shaw, Alice .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1170-S1171

[32] Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC) [J].

Doebele, Robert ;

Horn, Leora ;

Spira, Alexander ;

Piotrowska, Zofia ;

Costa, Daniel ;

Neal, Joel ;

Reichmann, William ;

Kerstein, David ;

Li, Shuanglian ;

Janne, Pasi .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1072-S1073

[33] Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC [J].

Rudin, C. ;

Cervantes, A. ;

Dowlati, A. ;

Besse, B. ;

Ma, B. ;

Costa, D. ;

Schmid, P. ;

Heist, R. ;

Villaflor, V. ;

Sarkar, I. ;

Hernandez, G. ;

Foster, P. ;

Spahn, J. ;

O'Hear, C. ;

Gettinger, S. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S407-S407

[34] Safety and Efficacy of Sitravatinib plus Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC [J].

Khan, N. ;

Newman, J. ;

Rahman, H. ;

Lee, C-S. ;

Kohn, N. ;

Seetharamu, N. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) :S373-S374

[35] Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial [J].

Tian, Zhichao ;

Dong, Shuping ;

Zuo, Wenli ;

Li, Po ;

Zhang, Fan ;

Gao, Shilei ;

Yang, Yonghao ;

Li, Chao ;

Zhang, Peng ;

Wang, Xin ;

Wang, Jiaqiang ;

Yao, Weitao .

FRONTIERS IN PHARMACOLOGY, 2022, 13

[36] Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902 [J].

Tsukita, Yoko ;

Umezawa, Rei ;

Nakagawa, Taku ;

Anbai, Akira ;

Makiguchi, Tomonori ;

Tanaka, Hisashi ;

Horii, Yosuke ;

Suzuki, Aya ;

Morita, Ryo ;

Nogawa, Hitomi ;

Yokouchi, Hiroshi ;

Kimura, Nozomu ;

Jingu, Keiichi ;

Inoue, Akira ;

Sugiura, Hisatoshi ;

Miyauchi, Eisaku .

JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (05)

[37] A Phase I Dose Expansion Study of Epitinib to Evaluate Efficacy and Safety in EGFR Mutation Positive (EGFRm plus ) NSCLC Patients with Brain Metastasis [J].

Zhou, Qing ;

Gan, Bin ;

Hong, Qunying ;

Wang, Mengzhao ;

Liu, Xiaoqing ;

Yuan, Liwei ;

Hua, Ye ;

Ren, Hongcan ;

Su, Weiguo ;

Wu, Yi Long .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S932-S933

[38] Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial [J].

Park, H. ;

Jung, J. S. ;

Kim, Y. M. ;

Kang, Y. ;

Ji, W. ;

Lee, J. C. ;

Choi, C. -M. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) :S463-S464

[39] Safety and Efficacy of Sitravatinib plus Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC [J].

Zhao, J. ;

Wu, J. ;

Cui, J. ;

Wang, L. ;

Sun, M. ;

Gao, B. ;

Ma, Z. ;

Liu, Y. ;

Wang, Z. ;

Li, X. ;

Li, H. ;

Zhang, J. ;

Sun, J. ;

Fei, C. ;

Wu, Y. -L. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) :S374-S374

[40] Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial [J].

Xu, Yan ;

Chen, Minjiang ;

Gao, Xiaoxing ;

Liu, Xiaoyan ;

Zhao, Jing ;

Zhong, Wei ;

Wang, Mei ;

Lang, Hongli ;

Yip, Chingwan ;

Wang, Mengzhao .

CANCER LETTERS, 2025, 630

← 1 2 3 4 5 →